1 Original article

2 The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens:

3 Safety and immunogenicity to Omicron BA.4/BA.5

- 4 Sitthichai Kanokudom^{a,b}, Jira Chansaenroj^a, Nungruthai Suntronwong^a, Suvichada Assawakosri
- ⁵^{a,b}, Ritthideach Yorsaeng ^a, Pornjarim Nilyanimit ^a, Ratchadawan Aeemjinda ^a, Nongkanok
- 6 Khanarat ^a, Preeyaporn Vichaiwattana ^a, Sirapa Klinfueng ^a, Thanunrat Thongmee ^a, Donchida
- 7 Srimuan^a, Thaksaporn Thatsanatorn^a, Natthinee Sudhinaraset^a, Nasamon Wanlapakorn^a,
- 8 Sittisak Honsawek^{b,*}, and Yong Poovorawan^{a,c,*}
- ^a Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,
- 10 Bangkok, 10330, Thailand.
- ^b Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine,
- 12 Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society,
- 13 Bangkok, 10330, Thailand.
- ^c Fellow of the Royal Society of Thailand (FRS [T]), the Royal Society of Thailand, Sanam

15 Sueapa, Dusit, Bangkok, 10300, Thailand.

16

Corresponding authors: Sittisak Honsawek (sittisak.h@chula.ac.th) and Yong Poovorawan
(yong.p@chula.ac.th)

19

20 Running head: Fourth dose COVID-19 mRNA vaccine after different three-dose regimens

22 Abstract

Objective: To investigate the reactogenicity and immunogenicity of the fourth dose using
 mRNA vaccines after different three-dose regimens and to compare the 30 µg BNT162b2 and 50
 µg mRNA-1273 vaccines.

26 Methods: This prospective cohort study was conducted between June and October 2022. The

self-recorded reactogenicity was evaluated on the subsequent 7 days after a fourth dose. Binding

and neutralizing activity of antibodies against the Omicron BA.4/5 variants were determined.

Results: Overall, 292 healthy adults were enrolled and received BNT162b2 or mRNA-1273.

30 Reactogenicity was mild to moderate and well-tolerated after a few days. Sixty-five individuals

were excluded. Thus, 227 eligible individuals received a fourth booster dose of BNT162b2

32 (n=109) and mRNA-1273 (n=118). Most participants, regardless the type of previous three dose

regimens, elicited a significantly high level of binding antibodies and neutralizing activity

against the Omicron BA.4/5 28 days after a fourth dose. The neutralizing activity against the

35 Omicron BA.4/5 between the BNT162b2 (82.8%) and mRNA-1273 (84.2%) groups was

comparable with a median ratio of 1.02.

Conclusion: This study found that the BNT162b2 and mRNA-1273 vaccines can be used as a
fourth booster dose for individuals who were previously immunized with any prior mix and
match three dose COVID-19 vaccine.

Keywords: Severe acute respiratory virus 2 (SARS-CoV-2); Omicron; safety; immunogenicity;
mRNA vaccine; Booster dose

43 **1.** Introduction

44	Coronavirus disease 2019 (COVID-19) is a flu-like disease caused by severe acute
45	respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 has rapidly evolved across
46	the world. Since the first identification of the Omicron variant in South Africa on 26 November
47	2021, several subvariants have been identified (Shrestha et al., 2022). The Omicron lineages
48	have caused outbreaks of COVID-19 in multiple countries around the world from early 2022 to
49	date (Tegally et al., 2022). On 6 January 2023, there were more than 667 million confirmed cases
50	worldwide with 4.7 million cases in Thailand, and 6.7 million reported deaths worldwide and
51	over 33,000 deaths in Thailand alone (Worldmeter, 2023).
52	In many countries, including Thailand, most initial vaccinations were administered
53	with two doses of inactivated vaccine (CoronaVac or BBIBP-CorV), two doses of viral vector
54	vaccine (AZD1222) or a heterologous schedule (CoronaVac followed by AZD1222) to ensure
55	adequate coverage. After the arrival of BNT162b2 and mRNA-1273 in Thailand and the spread
56	of the Delta variant SARS-CoV-2 in July 2021, the Ministry of Public Health recommended a
57	third dose vaccination campaign with AZD1222, BNT162b2, and mRNA-1273 administered
58	after three months of second dose vaccination. Subsequently, a fourth dose was offered on 21
59	March 2022, to combat the newly emerging Omicron variant, which evades pre-existing vaccine-
60	induced immunity (Magen et al., 2022). On 2 December 2022, more than 26 million individuals
61	(38.5%) of the Thai population had received three doses and approximately 5.8 million (8.4%)
62	had received four doses (Thai-DDC, 2023). Limited safety and immunogenicity studies are
63	currently available evaluating the fourth dose vaccination after three-dose mix-and-match
64	vaccinations.

65	The third booster dose elicits a high immune response against infection (Akaishi et
66	al., 2022; Wan et al., 2022). A field study demonstrated that the third dose increased vaccine
67	effectiveness against disease severity (Accorsi et al., 2022, Favresse et al., 2022), and reduced
68	hospitalization rates (Adams et al., 2022, Wan et al., 2022). Furthermore, a third dose vaccine
69	increases neutralizing capacity against the Omicron variant in laboratory tests (Assawakosri et
70	al., 2022a, Assawakosri et al., 2022b, Kanokudom et al., 2022a, Kanokudom et al., 2022b,
71	Suntronwong et al., 2022b). Waning immunity after three doses appears to significantly reduce
72	vaccine efficacy (VE) against infection at 3-6 months of follow-up (Favresse et al., 2022), and
73	probably leads to breakthrough infections with the Delta/Omicron variants (Amanatidou et al.,
74	2022). Recent studies have shown that a fourth dose of mRNA vaccine was associated with a
75	reduced rate of symptomatic infection during the Omicron predominant period (Bar-On et al.,
76	2022; Regev-Yochay et al., 2022). According to a cohort study of individuals aged 80 and older
77	in Sweden, a fourth mRNA booster dose increased VE against mortality during the Omicron era
78	compared to three doses of BNT162b2 (Nordström et al., 2022). Additionally, a previous report
79	showed that the fourth dose reduced the infection rate and severity (Cohen et al., 2022).
80	Furthermore, surveillance of a total of 36,170 subjects in Northern Thailand indicated that VE
81	against Omicron infection of the subjects receiving a fourth dose was 75%, followed by the three
82	doses (VE of 31%), and one or two doses conferred little to no protection, respectively)
83	(Intawong et al., 2022). However, the clinical outcomes of a fourth booster dose after different
84	three-dose regimes remain unclear.
05	Many individuals require a baseter door to restore hinding and restortining

Many individuals require a booster dose to restore binding and neutralizing
antibodies that are no longer sufficient to combat the emerging Omicron subvariants. This study
investigated the increased effects of the fourth dose of mRNA vaccines, BNT162b2 and mRNA-

88	1273, after three mix and match dose regimens. In addition, we compared the reactogenicity and
89	immunogenicity among these two booster groups. This study provides important data to help
90	guide policy makers on the use of fourth doses of COVID-19 vaccines among the adult
91	population in Thailand.
92	
93	2. Materials and methods
94	2.1 Study designs and participant enrolment
95	The cohort study was conducted between June and October 2022 at the Center for
96	Excellence in Clinical Virology, Chulalongkorn University, Bangkok. The study protocol was
97	approved by the Institutional Review Board (IRB) of the Faculty of Medicine of Chulalongkorn
98	University (IRB 223/65) and was conducted in accordance with the principles of the Declaration
99	of Helsinki. This trial was registered in the Thai Registry of Clinical Trials (TCTR
100	20210910002). Written informed consent was obtained from the participants before enrollment.
101	A total of 292 healthy adults 18 years and older, who had previously been
102	immunized with any of the three available doses of the COVID-19 vaccine for at least 3 months,
103	were enrolled. The cohort was stratified into 12 groups according to their primary three doses
104	(Figure 1). Participants with no history of COVID-19 disease received a fourth booster dose of
105	$30 \ \mu g \ BNT162b2$ or $50 \ \mu g \ mRNA-1273$. Exclusion criteria were characteristics associated with
106	serious medical conditions and individuals who had pre-existing immunoglobulin (Ig) G specific
107	to nucleoprotein (N) (anti-N IgG), anti-N IgG seroconversion (negative to positive) and
108	confirmed positive tests to SARS-CoV-2.

109 **2.2 Vaccines**

110	The BNT162b (Pfizer-BioNTech Inc., New York City, NY, USA) vaccine contains
111	$30 \ \mu g$ of mRNA encoding the SARS-CoV-2 spike protein (S) (Polack et al., 2020). The mRNA-
112	1273 (Moderna Inc., Cambridge, MA, USA) contains 50 µg of mRNA encoding SARS-CoV-2 S
113	protein, of which the half dose concentration has recently been recommended by the World
114	Health Organization Strategic Advisory Group of Experts on Immunization (SAGE) as a booster
115	dose for individuals aged 12 and older (Jackson et al., 2020, WHO, 2022). A dose of vaccine was
116	administered intramuscularly.
117	2.3 Safety assessments
118	The enrolled participants self-reported reactogenicity using an electronic or paper
119	questionnaire, starting on the day of vaccination and for 7 subsequent days (days 0-7). Local,
120	systemic and adverse events (AE) were classified as mild, moderate and severe, as previously
121	described (Kanokudom et al., 2022a).
122	2.4. Laboratory assessments
123	Serum samples were collected to determine binding antibody responses, including
124	total immunoglobulin (Ig) anti-RBD of the SARS-CoV-2 spike protein (total RBD Ig) using the
125	Elecsys SARS-CoV-2 S electrochemiluminescence immunoassay (ECLIA) according to the
126	manufacturer's instructions (Roche Diagnostics, Basel, Switzerland), the anti-RBD IgG using a
127	Quant chemiluminescent microparticle immunoassay (CMIA) (Abbott Laboratories, Abbott
128	Park, IL, USA), and anti-N IgG using CMIA (Abbott Diagnostics, Sligo, Ireland) as previously
129	described (Kanokudom et al., 2022a). Neutralizing activity against the SARS-CoV-2 Spike
130	protein RBD-HRP Omicron (BA.4/BA.5) (hereafter referred to as BA.4/5) (G339D, S371F,
131	S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A,
132	F486V, Q498R, N501Y, Y505H) (GenScript Biotech, Piscataway, NJ, USA) was analyzed using

133	a surrogate virus neutralization test (sVNT) as previously described (Assawakosri et al., 2022b,
134	Wanlapakorn N. et al., 2022b). Seropositivity of sVNT against Omicron (BA.4/5) was defined as
135	\geq 30% inhibition, respectively.

136 **2.5. Statistical analysis**

Baseline characteristics were reported as mean with standard deviation (SD) or 137 median with interquartile range (IQR). Categorical age and sex analyses were performed using 138 Pearson's Chi-square test. The difference in incidence of an adverse event after the fourth dose 139 with BNT162b2 or mRNA-1273 was analyzed using a risk difference (RD) with a 95% 140 confidence interval (CI). Total RBD Ig and anti-RBD IgG were designated as geometric mean 141 titers (GMT) with a 95% CI. The percentage inhibition using sVNT was presented as median 142 143 with interquartile range (IQR) values. The geometric mean ratio (GMR) of total-RBD Ig and anti-RBD IgG was calculated using the Mann–Whitney U test. Significant differences between 144 the two groups in antibody titers and percentage inhibition were compared using the Mann-145 146 Whitney U test. Non-parametric correlation between the GMT of total RBD Ig or anti-RBD IgG 147 and the percent inhibition was calculated using Spearman's rank correlation coefficient (Spearman's ρ). The linear equation and coefficient of determination (r-square, R^2) between the 148 149 transformation of the logarithmic GMT of total-RBD Ig or anti-RBD IgG and percent inhibition 150 was calculated based on a simple linear regression model. A p-value<0.05 was considered 151 statistically significant.

152

153

155 **3.** Results

156 **3.1 Demographic data and baseline characteristics**

157	Between June and October 2022, a total of 292 healthy individuals from 12 different
158	three-dose regimes (provided in Figure 1) were enrolled to receive a fourth booster dose of
159	BNT162b2 or mRNA-1273. Sixty-five individuals were excluded and consisted of 24 subjects
160	with pre-existing anti-N IgG, 8 subjects with anti-N IgG seroconversion from negative to
161	positive, and 33 cases lost to follow-up. After exclusions, 227 individuals remained and were
162	divided in two booster dose groups: BNT162b2 (n=109) and mRNA-1273 (n=118).
163	The demographics and characteristics of the eligible participants who received
164	BNT162b2 or mRNA-1273, including sex, age, comorbidity, the time interval between the third
165	and fourth dose, and the time interval between the fourth dose and blood collection (28 \pm 7 days)
166	are shown in Table 1. The number of females (%) in the BNT162b2 and mRNA-1273 groups
167	was 66.1% and 60.2%, respectively. The mean age of the BNT162b and mRNA-1273 groups
168	was 48.8 and 48.2 years, respectively. There were no significant differences in terms of sex and
169	age between the groups. The median interval between the third and fourth doses of BNT162b2
170	(191.0 days) was significantly shorter than that of the mRNA-1273 group (210.5 days).
171	3.2 Local and systemic adverse events resolved after receiving the mRNA-COVID-19
172	vaccine as the fourth booster dose
173	Profiles of local and systemic reactions within 7 days after vaccination with BNT162b2 and
174	mRNA-1273 in each regimen included injection site pain, myalgia, and swelling
175	(Supplementary Figure S1A-L). The safety profile of healthy participants who received a
176	booster dose of BNT162b2 (n=139) or mRNA-1273 (n=150) was defined using a self-
177	questionnaire. The most frequent adverse events were mild to moderate injection site pain

(77.0% vs. 81.3%), followed by myalgia (63.3% vs. 62.0%), and swelling (39.6% vs. 54.0%) for

179	the BNT162b2 and mRNA-1273 groups, respectively (Figure 2A,B). Furthermore, other adverse
180	events observed in both groups were well tolerated and resolved in a few days. To compare the
181	incidence between the two booster groups, swelling (RD: 14.4, 95%CI: 3.0-25.8), fever (RD:
182	4.0, 95%CI: 0.9–7.1) and headache (RD: 11.2, 95%CI: 0.4–22.1) were more frequent in the
183	mRNA-1273 group than in the BNT162b2 group (Figure 2C).
184	3.3 Total-RBD Ig and anti-RBD IgG responses of eligible participants
185	A total of 227 individuals were seronegative anti-N IgG (no history of SARS-CoV-2
186	infection) and further examined for binding antibodies levels, including total RBD Ig and anti-
187	RBD IgG. At baseline, the GMT of the total RBD Ig between 12 regimens ranged from 480.4 to
188	3112 U/mL. At 28 days after the fourth dose, all eligible individuals achieved a GMT of the total
189	RBD Ig ranging from 11,992 to 32,003 U/mL (Supplementary Figure S1A). Furthermore, the
190	GMT for the baseline anti-RBD IgG among all eligible individuals of the 12 regimens ranged
191	from 77.9 to 492.2 BAU/mL. After the booster dose, the GMT of anti-RBD IgG for the 12
192	groups increased between 1562 and 4664 BAU/mL (Supplementary Figure S1B). Although
193	individuals had several three-dose schedules, the fourth dose generated a higher antibody titer
194	specific for SARS-CoV-2 RBD for all regimens at 28 days.
195	To compare immunogenicity resulting from the fourth dose, sera samples were
196	collected for the two groups according to the booster dose of BNT162b (n=109) and mRNA-
197	1273 (n=118). The baseline total RBD Ig GMT between the BNT162b2 and mRNA-1273 groups

- was similar (GMR: 0.93). After 28 days, the total RBD Ig GMT of the mRNA-1273 group was
- significantly higher than that of the BNT162b2 group (GMR: 1.17, p < 0.05) (Figure 3A).

200	Similarly, the anti-RBD IgG response trends at baseline and after 28 days of receiving a fourth
201	dose were consistent with the total RBD Ig response (Figure 3B).

- **3.4 Neutralizing activity against Omicron BA.4/5 using sVNT₅₀**
- A subset of participants who received a fourth dose of BNT162b2 (n=67) and
- mRNA-1273 (n=93) was randomly selected for testing neutralizing activities against SARS-
- 205 CoV-2 Omicron BA.4/5 using sVNT₅₀. At baseline, the serone gativity (at threshold < 30%)
- against Omicron BA.4/5 was 19/67 (28.4%) for BNT162b2 and 33/93 (35.5%) for the mRNA-
- 1273 groups. The median baseline neutralizing activity was 41.8% (IQR: 26.2–49.8%) for
- 208 BNT162b2 and 35.9% (IQR: 22.0–50.2%) for the mRNA-1273 groups (**Figure 4**).

209 The neutralizing activity of boosted individuals receiving BNT162b2 and mRNA-

- 1273 was significantly restored to 82.8% (p<0.001) and 84.2% (p<0.001) at 28 days,
- respectively. Furthermore, the median percentage inhibition against Omicron BA.4/5 between
- the BNT162b2 and mRNA-1273 groups was comparable to baselines (median ratio: 0.86) and
- after receiving a booster dose (median ratio: 1.02) (**Figure 4**).

3.5 Correlations between binding antibody and neutralizing activity against Omicron BA.4/5

To substantially assess the correlation between binding antibody and neutralizing activity against Omicron BA.4/5, a total of 320 sera were randomly selected from individual samples before (day 0) and after (day 28) receiving BNT162b2 or mRNA-1273. Quantitative ELISA levels of total RBD Ig and anti-RBD IgG, and *in vitro* ACE2-RBD binding neutralizing activity, which measured sVNT₅₀, were further examined to determine the correlation between techniques. The percent inhibition for the Omicron BA.4/5 ranged from 0.0% (undetectable) to 99.6% compared to total RBD-Ig and anti-RBD IgG, respectively. The non-parametric

223	correlation indicated that the percent inhibition against the Omicron BA.4/5 subvariant was
224	strongly correlated with total RBD Ig (Spearman's ρ : 0.83, p <0.001). A linear regression
225	equation showing the percent inhibition against Omicron BA.4/5 based on $\log_{10}(\text{total RBD Ig})$ is
226	presented in Supplementary Figure 3A (R^2 : 0.70). The correlation between the percent
227	inhibition against the Omicron BA.4/5 and anti-RBD IgG showed a similar trend as total-RBD Ig
228	(Spearman's ρ : 0.82, p <0.001 and R ² : 0.68) (Supplementary Figure 3B).
229	4. Discussion
230	We compared the reactogenicity of BNT162b2 and half-dose mRNA-1273 resulting
231	from the administration of a fourth booster dose in healthy adults who had previously received
232	different vaccine schedules. These findings revealed that common side effects were injection site
233	pain, myalgia, headache, swelling, and redness at the injection site, which was in agreement with
234	previous studies evaluating the application of mRNA vaccines as the third (Kanokudom et al.,
235	2022a, Munro et al., 2021) and the fourth (Munro et al., 2022) doses.
236	This study evaluated the binding antibody targeting the SARS-CoV-2 spike protein
237	in terms of total RBD Ig and anti-RBD IgG. For individuals who had received the third dose for
238	approximately 3–12 months (min-max: 94–371 days), binding antibody levels were notably low.
239	The present study showed that a fourth dose with the mRNA vaccine could restore the total RBD
240	Ig titer from 11,992 to 32,003 U/mL among all regimens. Comparison of the two boosted groups
241	showed that half-dose mRNA-1273 (50 μ g) could induce a slightly higher response than in those
242	immunized with BNT162b2 (30 μ g). This evidence was possibly due to a dose-dependent
243	response of active RNA molecules, as demonstrated previously (Kanokudom et al., 2022a). The
244	GMT of total RBD Ig among 12 groups was varied due to abundant factors consisting of time
245	intervals between the previous dose and the last dose, the vaccination dose, and the primary

regimens. Additionally, in agreement with a previous study by Wanlapakorn et al. (2022), the 246 present study indicated that individuals who were primed with an inactivated vaccine followed 247 by an mRNA vaccine showed stronger immunogenicity compared to individuals who were 248 primed with a viral vector or heterologous inactivated/viral vector vaccination schedule 249 In the present study, the boosted neutralizing activity against the variant Omicron 250 BA.4/5 after the fourth dose with the BNT162b2 and mRNA-1273 was observed on day 28. Our 251 finding was in agreement with that of a previous study showing that there was no significant 252 difference between BNT162b2 and mRNA-1273 in neutralizing activity against the Omicron 253 variant (Wan et al., 2022). A fourth dose of BNT162b2 may increase the effectiveness of the 254 255 vaccine against severe diseases compared to three doses (Magen et al., 2022). The fourth dose of BNT162b2 and mRNA-1273 subsequent to any three-dose regimen used in this study was 256 257 expected to achieve a similar response to severe illness.

Our study evaluated the correlation between anti-RBD antibodies determined by two 258 259 routine quantitative ELISA methods (expressed in total RBD Ig or anti-RBD IgG) and 260 neutralizing activity determined by sVNT (expressed in percent inhibition of ACE2-RBD 261 binding). Although two routine ELISA kits measured antibody titers against Wuhan-RBD and 262 sVNT measured neutralizing antibody levels against Omicron BA.4/5, a strong correlation between the routine ELISA findings and sVNT was observed. Furthermore, our previous study 263 264 evaluating different three-dose vaccinations showed a correlation between sVNT and the gold 265 standard live virus neutralization test also called the foci-reduction neutralization test (FRNT₅₀) against Omicron BA.1 and BA.2 (Spearman's p: 0.77 and 0.64, respectively) (Suntronwong et 266 al., 2022a). These data might suggest that the commercial sVNT assay was a suitable alternative 267 to the conventional neutralization test. 268

269	The current findings demonstrated that boosted individuals with either mRNA
270	vaccine could achieve a high level of binding antibody and neutralizing activity regardless of the
271	primary three-dose vaccine regimens. Our findings were consistent with the VE study that
272	showed that four-doses increased VE against Omicron infection compared to the three-doses or
273	less (Intawong et al., 2022). In summary, these findings provide evidence for recommending the
274	use of the mRNA vaccine as a fourth dose in healthy adults who completed three doses of mix-
275	and-match as primary regimens.
276	This study was subject to certain limitations. It was challenging to find CIVID-19
277	naïve participants that had avoided multiple COVID-19 waves. Approximately 20% of the
278	participants were excluded due to a suspected history of COVID-19 or were lost follow-up.
279	Long term immunity and durability of immune responses after a fourth booster dose should be
280	further determined. Additional studies on VE against infection and disease severity should be
281	conducted to verify the findings.
282	5. Conclusions
283	This study found no significant difference in neutralizing activities against Omicron
284	BA.4/5 among sera of individuals receiving either the BNT162b2 or mRNA-1273 vaccine as a
285	fourth dose. The two routine ELISA methods, used to test total RBD Ig and anti-RBD IgG, could
286	quantitatively predict neutralizing activity against Omicron BA.4/5. Overall, this study suggests
287	that BNT162b2 and mRNA-1273 could be used as booster doses after different three-dose
288	regimens.
289	Acknowledgments: We would like to thank all Center of Excellence in Clinical Virology
290	personnel and all participants for contributing to and supporting this project. This research was

financially supported by the Health Systems Research Institute (HSRI), National Research

292 Council of Thailand (NRCT), MK restaurant Group Aunt Thongku	m Foundation	, BJC Big C
--	--------------	-------------

- Foundation, the Center of Excellence in Clinical Virology, Chulalongkorn University, and King
- 294 Chulalongkorn Memorial Hospital, and was partially supported by the Second Century Fund
- 295 (C2F) of Sitthichai Kanokudom, Chulalongkorn University.
- Author Contributions: Conceptualization, S.K. (Sitthichai Kanokudom), P.N., S.H., and Y.P.;
- data curation, S.K. (Sitthichai Kanokudom), R.Y., N.S. (Nungruthai Suntronwong), S.A., D.S.,
- 298 T.T. (Thaksaporn Thatsanatorn), N.S. (Natthinee Sudhinaraset) and N.W.; formal analysis, S.K.
- 299 (Sitthichai Kanokudom); methodology, S.K. (Sitthichai Kanokudom), J.C., R.A., N.K., P.V.,
- 300 S.K. (Sirapa Klinfueng) and T.T (Thanunrat Thongmee); project administration, Y.P.; writing—
- original draft, S.K. (Sitthichai Kanokudom); writing—review and editing, S.K. (Sitthichai
- Kanokudom), S.H. and Y.P. All authors have read and agreed to the published version of the manuscript.
- **Funding:** This study was financially supported by the Health Systems Research Institute
- 305 (HSRI), National Research Council of Thailand (NRCT), MK restaurant Group Aunt Thongkum

Foundation, BJC Big C Foundation, the Center of Excellence in Clinical Virology,

307 Chulalongkorn University, and King Chulalongkorn Memorial Hospital, and partially supported

³⁰⁸ by the Second Century Fund (C2F) of Sitthichai Kanokudom, Chulalongkorn University.

Institutional Review Board Statement: The study protocol was approved by the Institutional

- Review Board (IRB), Faculty of Medicine, Chulalongkorn University (IRB number 223/65).
- 311 Informed Consent Statement: Informed consent was obtained before participant enrollment.
- 312 The study was conducted according to the Declaration of Helsinki and the Good Clinical Practice
- 313 Guidelines (ICH-GCP) principles.

314	Data Availability Statement: The datasets generated and analyzed during the current study are
315	available from the corresponding author upon reasonable request.
316	Conflicts of Interest: The authors declare no conflict of interest.
317	References
318	Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association
319	between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by
320	the SARS-CoV-2 Omicron and Delta variants. JAMA 2022;327:639-51.
321	Adams K, Rhoads JP, Surie D, Gaglani M, Ginde AA, McNeal T, et al. Vaccine effectiveness of
322	primary series and booster doses against COVID-19 associated hospital admissions
323	in the United States: living test negative design study. BMJ 2022;379:e072065.
324	Akaishi T, Kushimoto S, Katori Y, Sugawara N, Egusa H, Igarashi K, et al. Effectiveness of
325	third vaccine dose for Coronavirus disease 2019 during the Omicron variant
326	pandemic: a prospective observational study in Japan. Sci Rep 2022;12:13589.
327	Amanatidou E, Gkiouliava A, Pella E, Serafidi M, Tsilingiris D, Vallianou NG, et al.
328	Breakthrough infections after COVID-19 vaccination: insights, perspectives and
329	challenges. Metabolism Open 2022;14:100180.
330	Assawakosri S, Kanokudom S, Chansaenroj J, Suntronwong N, Auphimai C, Nilyanimit P, et al.
331	Persistence of immunity against Omicron BA.1 and BA.2 following homologous and
332	heterologous COVID-19 booster vaccines in healthy adults after a two-doses
333	AZD1222 vaccination. Int J Infect Dis 2022a;122:793-801.
334	Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et
335	al. Neutralizing activities against the Omicron variant after a heterologous booster in
336	healthy adults receiving two doses of CoronaVac vaccination. J Infect Dis 2022b.

337	Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al. Protection by		
338	a fourth dose of BNT162b2 against Omicron in Israel. N Engl J Med		
339	2022;386:1712–20.		
340	Cohen MJ, Oster Y, Moses AE, Spitzer A, Benenson S, Group I-HtVW. Association of receiving		
341	a fourth dose of the BNT162b vaccine with SARS-CoV-2 infection among health		
342	care workers in Israel. JAMA Netw Open 2022;5:e2224657-e.		
343	Favresse J, Gillot C, Bayart J-L, David C, Simon G, Wauthier L, et al. Vaccine-induced binding		
344	and neutralizing antibodies against Omicron 6 months after a homologous		
345	BNT162b2 booster. J Med Virol 2022;95:e28164.		
346	Intawong K, Chariyalertsak S, Chalom K, Wonghirundecha T, Kowatcharakul W,		
347	Thongprachum A, et al. Effectiveness of heterologous third and fourth dose COVID-		
348	19 vaccine schedules for SARS-CoV-2 infection during delta and omicron		
349	predominance in Thailand: A test-negative, case-control study. Lancet Reg Health		
350	Southeast Asia 2022; 100121. Available from: https:		
351	doi:10.1016/j.lansea.2022.100121		
352	Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA		
353	vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020;383:1920–31.		
354	Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, et al.		
355	Comparison of the reactogenicity and immunogenicity of a reduced and standard		
356	booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of		
357	inactivated vaccine. Vaccine 2022a;40:5657-63.		
358	Kanokudom S, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, et al.		
359	Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine		

360	(Covovax(TM)) after homologous and heterologous two-dose regimens. Int J Infect
361	Dis 2022b;126:64–72.
362	Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hernán MA, et al. Fourth dose of
363	BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med
364	2022;386:1603–14.
365	Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety, immunogenicity,
366	and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as
367	fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a
368	third dose of BNT162b2 (COV-BOOST): A multicentre, blinded, phase 2,
369	randomised trial. Lancet Infect Dis 2022;22:1131-41.
370	Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and
371	immunogenicity of seven COVID-19 vaccines as a third dose (booster) following
372	two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a
373	blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021;398:2258-
374	76.
375	Nordström P, Ballin M, Nordström A. Effectiveness of a fourth dose of mRNA COVID-19
376	vaccine against all-cause mortality in long-term care facility residents and in the
377	oldest old: A nationwide, retrospective cohort study in Sweden. Lancet Reg Health
378	Eur 2022;21:100466.
379	Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy
380	of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383(27):2603-15.

381	Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy of		
382	a fourth dose of Covid-19 mRNA vaccine against Omicron. N Engl J Med		
383	2022;386:1377–80.		
384	Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2		
385	Omicron variants BA.1 to BA.5: Implications for immune escape and transmission.		
386	Rev Med Virol 2022;32:e2381.		
387	Suntronwong N, Assawakosri S, Kanokudom S, Yorsaeng R, Auphimai C, Thongmee T, et al.		
388	Strong correlations between the binding antibodies against wild-type and neutralizing		
389	antibodies against Omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals		
390	following booster (third-dose) vaccination. Diagnostics 2022a;12:1781.		
391	Suntronwong N, Kanokudom S, Auphimai C, Assawakosri S, Thongmee T, Vichaiwattana P, et		
392	al. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses		
393	to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222		
394	vaccination. J Med Virol 2022b;94:5713–22.		
395	Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Emergence of		
396	SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med		
397	2022;28:1785–90.		
398	Thailand Department of Disease Control (Thai-DDC). COVID-19 vaccine in Thailand.; 2023.		
399	Available from: <u>https://ddc.moph.go.th/vaccine-</u>		
400	covid19/getFiles/7/1670402801471.jpg [Accessed 6 January 2023].		
401	Wan EYF, Mok AHY, Yan VKC, Wang B, Zhang R, Hong SN, et al. Vaccine effectiveness of		
402	BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection,		

403	hospitalisation, severe complications, cardiovascular disease and mortality in patients
404	with diabetes mellitus: A case control study. J Infect 2022;85:e140-e4.
405	Wanlapakorn N, Suntronwong N, Kanokudom S, Assawakosri S, Nilyanimit P, Yorsaeng R, et
406	al. Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster)
407	following two doses of different primary series regimens in Thailand. Pathog Glob
408	Health 2022;116:395–7.
409	The WHO Strategic Advisory Group of Experts on Immunization (SAGE). The Moderna
410	COVID-19 (mRNA-1273) vaccine: what you need to know.; 2022. Available from:
411	https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-
412	1273-vaccine-what-you-need-to-know. [Accessed 18 August 2022].
413	Worldmeter. COVID-19 Coronavirus pandemic.; 2023. Available from:
414	https://www.worldometers.info/coronavirus/ [Accessed 9 January 2023].
415	


416 **Figures and Tables**

417 Table 1. Characteristics of the individuals who received a fourth booster COVID-19

418 vaccine.

Characteristic	BNT162b2	mRNA-1273			
Number	109	118			
Sex, female n (%)	72 (66.1)	71 (60.2)			
Age, years, mean [SD]	48.8 [11.5]	48.2 [11.8]			
(min-max)	(20.0–73.0)	(23.0–74.0)			
No comorbidity (%)	68 (62.4)	86 (72.9)			
Underlying diseases (%)					
Allergy	5 (4.6)	5 (4.2)			
Dyslipidemia	12 (11.0)	11 (9.3)			
Diabetes Mellitus	4 (3.7)	4 (3.4)			
Hypertension	11 (10.1)	15 (12.7)			
Thyroid	2 (1.8)	2 (1.7)			
Others	10 (9.2)	4 (3.4)			
Interval between the 3 rd and 4 th dose (days)					
Median [IQR]	191.0 [163.0–223.0]	210.5 [177.0–224.3]			
(min-max)	(94.0–337.0)	(117.0–371.0)			
Interval between the 4 th dose and blood collection (days)					
Median [IQR]	28.0 [28.0–29.0]	28.0 [28.0–32.0]			
(min-max)	(22.0–32.0)	(26.0–34.0)			

Abbreviation: IQR, interquartile range; SD, standard deviation.





420

Figure 1. Study flow diagram of participants enrolled and collection of eligible samples.


- 422 Individuals (18 years and older), who had previously been immunized with different three doses,
- were assigned to receive the fourth booster dose with $30 \mu g$ BNT162b2 or $50 \mu g$ mRNA-1273.
- Blood samples were collected on days 0 and 28 ± 7 after booster dose. Serum samples were

- 425 previously screened according to the level of anti-nucleoprotein (N) IgG. Participants who had
- seropositive anti-N IgG (pre-existing and seroconversion) were excluded. The remaining
- 427 participants were eligible for the evaluation of immunogenicity analyses after booster
- 428 vaccination.
- 429 Abbreviations: AEs, adverse events; A and AZ, AZD1222; Ig; immunoglobulin; M and MN,
- 430 mRNA-1273; N, nucleoprotein; P and PF, BNT162b2; S, inactivated vaccine BBIBP-CorV (SP)
- 431 or CoronaVac (SV).





С





433

Figure 2. Overall reactogenicity of individuals who received a fourth dose of either


435 **BNT162b2 or mRNA-1273.**

- The percentages of local, systemic, and any adverse events (AE) experienced within 7 days of
- 437 receiving (A) BNT162b2 or (B) mRNA-1273. (C) Forest plots showing the incidences of each
- AE and the risk differences with 95% confidence intervals (95% CI).





- 442 BNT162b2 and mRNA-1273 booster groups.
- (A) Total immunoglobulin (Ig) specific for the receptor binding domain (RBD) (Total RBD Ig)
- 444 (U/mL) and (B) anti-RBD IgG (BAU/mL) of the BNT162b2 and mRNA-1273 booster groups
- were monitored at baseline (D0) and 28 days after vaccination (D28). The gray area indicates the
- seronegativity of total RBD Ig (<0.8 U/mL) or anti-RBG IgG (<7.1 BAU/mL) antibodies. Lines
- represent the geometric mean titer (GMT) with 95% confidence intervals (95% CI). A pairwise
- 448 comparison shows geometric mean ratio (GMR) and statistical significance set at p < 0.05 (*),
- 449 p < 0.001 (**), and no statistical significance (ns).
- 450 Abbreviation: BAU, binding antibody unit; CI, confidence interval; D0, day 0; D28, day 28;
- GMT, geometric mean titer; GMR, geometric mean ratio; Ig, immunoglobulin; ns, no statistical
 significance.
- 453





455 Figure 4. Neutralizing activity of participants against the SARS-CoV-2 Omicron BA.4/5 at

456 **28 days after the fourth dose.** Sera were obtained from a subset of individuals at baseline (D0)

- and at 28 days (D28) after receiving a booster dose of BNT162b2 and mRNA-1273. The gray
- 458 area indicates the neutralizing activity of the SARS-CoV-2 Omicron BA.4/5 (<30%). Lines
- represent the medians (%) with interquartile range (IQR) values. A pairwise comparison displays
- the median ratio and the lack of statistical significance (ns).
- Abbreviation: D0, day 0; D28, day 28; GMT, geometric mean titer; GMR, geometric mean ratio;
- 462 IQR; interquartile range; ns, no statistical significance.

464 Supplementary materials

- Figure S1. Solicited local, systemic, and adverse events of enrolled participants in different
- regimens. (A) SSAP, (B) SSAM, (C) SSPP, (D) SSMM, (E) AAAP, (F) AAAM, (G) AAPP, (H)
- 467 AAMM, (I) SAAP, (J) SAAM, (K) SAPP, and (L) SAMM groups and the proportion of mild,
- 468 moderate and severe adverse event 7 days after a booster dose for each group.
- Abbreviations: A, AZD1222; M, mRNA-1273; P, BNT162b2; S, inactivated vaccine BBIBP-
- 470 CorV or CoronaVac.

471

472 Figure S2. Binding antibody titers against the receptor binding domain of SARS-CoV-2 of

473 the 12 different four-dose regimens. (A) Total immunoglobulin (Ig) specific for receptor

- binding domain (RBD) (Total RBD Ig) (U/mL) and (B) anti-RBD IgG (BAU/mL) were assessed
- for 12 different vaccine regimens on days 0 and 28 ± 7 . The X-axis indicates the code of
- 476 participant regimens, followed by the day of collection (0 and 28) The gray area indicates the
- seronegativity of total RBD Ig (<0.8 U/mL) or anti-RBG IgG (<7.1 BAU/mL). Each column
- shows a scatter plot with a geometric mean titer (GMT). The lines represent GMT with 95%
- 479 confidence intervals (95% CI). Parentheses indicate the number of individuals in each regimen.
- Abbreviations: A, AZD1222; BAU, binding antibody unit; M, mRNA-1273; P, BNT162b2; S,
- 481 inactivated vaccine BBIBP-CorV or CoronaVac.

482

Figure S3. Predicted linear correlation between the binding antibody and neutralizing
activity against Omicron BA.4/5 using the sVNT₅₀. A total of 320 sera (at day 0 (n=160) and
day 28 (n=160)) from individuals who received a fourth dose of BNT162b2 and mRNA-1273

- 486 were tested for total RBD Ig and anti-RBD IgG levels and neutralizing activity against Omicron
- 487 BA.4/5 using sVNT₅₀. Linear regressions (solid line) showing the relationship between percent
- inhibition against Omicron BA.4/5 and logarithm (log₁₀) (Total RBD Ig) (A) or log₁₀ (Anti-RBD
- 489 IgG) (B). The linear equation and the r-square (R^2) were calculated according to a simple linear
- regression model between the transformed \log_{10} of the binding antibody and the percentage of
- inhibition. The dotted line indicates the seronegativity of neutralizing activity of SARS-CoV-2
- 492 Omicron BA.4/5 (<30%).
- Abbreviations: BAU, binding antibody unit; Ig, immunoglobulin.
- 494